RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 129 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,014,064 | +14.4% | 3,138,690 | +11.7% | 0.00% | +50.0% |
| Q2 2023 | $20,984,305 | +14.7% | 2,809,143 | +2.4% | 0.00% | 0.0% |
| Q1 2023 | $18,299,045 | +90840.5% | 2,743,484 | +5.1% | 0.00% | -33.3% |
| Q4 2022 | $20,122 | -99.9% | 2,609,948 | +11.9% | 0.00% | -25.0% |
| Q3 2022 | $24,813,000 | +102.4% | 2,332,083 | +54.9% | 0.00% | +100.0% |
| Q2 2022 | $12,258,000 | +32.3% | 1,505,996 | +16.4% | 0.00% | +100.0% |
| Q1 2022 | $9,263,000 | -58.2% | 1,293,756 | -0.1% | 0.00% | -66.7% |
| Q4 2021 | $22,182,000 | +71.4% | 1,294,957 | +130.3% | 0.00% | +50.0% |
| Q3 2021 | $12,939,000 | -28.7% | 562,331 | +13.2% | 0.00% | 0.0% |
| Q2 2021 | $18,138,000 | – | 496,949 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |